Cancer Research Annual Meeting 2010  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 3648-3653, September 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yalowich, J. C.
Right arrow Articles by Goldman, I. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yalowich, J. C.
Right arrow Articles by Goldman, I. D.

Teniposide (VM-26)- and Etoposide (VP-16-213)-induced Augmentation of Methotrexate Transport and Polyglutamylation in Ehrlich Ascites Tumor Cells in Vitro1

Jack C. Yalowich2, David W. Fry and I. David Goldman3

Department of Medicine, Medical College of Virginia, Richmond, Virginia 23298

Teniposide (VM-26) and etoposide (VP-16-213) were evaluated for their effects on methotrexate transport and metabolism in Ehrlich ascites tumor cells in vitro. VM-26 (10 µM) does not alter influx of methotrexate but slows efflux of the drug which leads to an increase in the steady-state level of exchangeable antifolate. VM-26 stimulation of net methotrexate transport occurs within 5 min of exposure of cells to VM-26 concentrations of from 10 to 50 µM; removal of extracellular VM-26 results in a rapid and complete reversal of this effect. As extracellular VM-26 is raised to 50 µM, the progressive rise in net methotrexate uptake observed is due not only to elevated exchangeable antifolate but to an enlarged nonexchangeable pool of intracellular drug as well, a major portion of which is methotrexate polyglutamyl derivatives. VM-26 does not alter the intracellular water or the chloride distribution ratio. Glucose partially reverses the stimulatory effect of VM-26 but to a lesser extent than glucose reversal of the vincristine-induced stimulation of net methotrexate transport.

VP-16-213 also stimulates net methotrexate transport in a manner qualitatively similar to that of VM-26. However, 100 µM VP-16-213 is required to yield the same quantitative stimulation as seen for 10 µM VM-26. VP-16-213-induced augmentation of intracellular methotrexate polyglutamate levels is also demonstrated.

These results indicate that VM-26 and VP-16-213 enhance net cell accumulation of methotrexate and methotrexate polyglutamyl derivatives in the Ehrlich ascites tumor in vitro at concentrations of these agents which are achieved in vivo. Potential therapeutic synergism between methotrexate and epipodophyllotoxins on this basis is therefore possible and is currently under evaluation in animal tumor systems.

1 Supported in part by Grant CA-16906 and a grant from Bristol Laboratories.

2 Supported by NIH Training Grant CA-09340.

3 To whom requests for reprints should be addressed.

Received 12/10/81. Accepted 5/ 3/82.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.